Evidence map›Paper›PMID 42818882›Full record

ArticleFrontiers in aging neuroscience2026

Hybrid multimodal late fusion frameworks for bvFTD classification in imbalanced dementia datasets.

Majid Ramedani, Jaya C Terli, Devesh Singh, Oliver Peters, Julian Hellmann-Regen, Josef Priller, Eike Jakob Spruth, Annika Spottke, Anne Boehlen, Patrick Weydt and 26 more

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Majid RamedaniGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Jaya C TerliGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Devesh SinghGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Oliver PetersDepartment of Psychiatry and Neurosciences, Charité Universitätsmedizin Berlin, Berlin, Germany.
Julian Hellmann-RegenDepartment of Psychiatry and Neurosciences, Charité Universitätsmedizin Berlin, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Annika SpottkeDepartment of Parkinson's, Sleep and Movement Disorders, Centre for Neurology, University Hospital Bonn, Bonn, Germany.
Anne BoehlenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Patrick WeydtDepartment of Parkinson's, Sleep and Movement Disorders, Centre for Neurology, University Hospital Bonn, Bonn, Germany.
Ullrich WüllnerDepartment of Parkinson's, Sleep and Movement Disorders, Centre for Neurology, University Hospital Bonn, Bonn, Germany.
Elisabeth DinterDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Rene GüntherDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
Björn H SchottDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
Emrah DüzelGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Daniel JanowitzGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Anna StockbauerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Mihovil MladinovGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Johannes PrudloGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Andreas HermannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Matthis SynofzikDivision of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tuebingen, Germany.
David MengelDivision of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tuebingen, Germany.
Gabor C PetzoldGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Falk LüsebrinkGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Peter DechentDepartment of Cognitive Neurology, MR-Research in Neurosciences, University Medical Center Goettingen, Göttingen, Germany.
Michael EwersGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, Tuebingen, Germany.
Sophia StöckleinDepartment of Radiology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Martin DyrbaGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
The Frontotemporal Lobar Degeneration Neuroimaging InitiativeR01AG032306 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2009 to 2013
$10.0M
NIA NIH HHS R01 AG032306NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Background: Behavioral variant frontotemporal dementia (bvFTD) is an irreversible neurodegenerative disorder characterized by progressive changes in personality and behavior. Magnetic Resonance Imaging (MRI) is widely used to detect and assess structural brain alterations associated with the disease. However, due to the low prevalence of bvFTD among neurodegenerative diseases causing the dementia syndrome, conventional machine learning approaches may struggle to capture comprehensive feature representations. Therefore, this study proposes two late fusion frameworks that integrate a 3D convolutional neural network and a multilayer perceptron (MLP) for improved bvFTD diagnosis. Methods: A total of 5,928 participants were included, comprising 3,415 healthy controls (HC), 2,276 Alzheimer's disease (AD), and 237 bvFTD, resulting in a class imbalanced setting with bvFTD as the minority class. To address class imbalance, bvFTD data were initially augmented. A 3D-DenseNet was used to extract features from 3D T1-weighted MRI scans, while an MLP-based model was applied to regional brain volumetric measurements obtained from automated MRI-based brain segmentation. Twelve CNN models with different hyperparameter configurations were trained. Models with and without data augmentation, as well as two fusion-based approaches, were evaluated using accuracy, F1-score, and area under the curve (AUC). Results: Both fusion strategies improved accuracy, F1-score, and AUC compared to the baseline model without data augmentation. Notable improvement was also observed for the bvFTD class, with up to a 120% increase in F1-score. In one of the fusion frameworks, an accuracy of 0.95 ± 0.01 was achieved for bvFTD vs. HC classification. The results demonstrate the effectiveness of the fusion-based approaches compared to non-fused models, outperforming several state-of-the-art methods. Conclusion: The proposed frameworks demonstrate that data augmentation and fusion strategies can improve accuracy, F1-score, and AUC, with statistically significant gains. Overall, the frameworks improve diagnostic performance and support the identification of relevant biomarkers associated with bvFTD pathology.

Indexed as

3D-CNNbvFTDclassificationlate fusionmagnetic resonance imaging

Identifiers

PMID42818882
PMCPMC13624165

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.